Related Experiment Videos
Cholestasis associated with total parenteral nutrition
Insights
Neonates, particularly those with very low birthweights, face high risks of cholestasis from total parenteral nutrition (TPN). Early enteral feedings, even minimal ones, may help prevent or treat this TPN-associated liver issue.
Area of Science:
- Neonatalogy
- Pediatric Gastroenterology
- Clinical Nutrition
Background:
- Neonates, especially premature infants with very low birthweights, are at significant risk for cholestasis.
- Cholestasis is a serious complication associated with total parenteral nutrition (TPN), a method of intravenous feeding.
Purpose of the Study:
- To explore the risks and potential preventative strategies for TPN-associated cholestasis in neonates.
- To investigate the role of early enteral nutrition in mitigating cholestasis in infants receiving TPN.
Main Methods:
- Review of existing literature and clinical observations regarding TPN in neonates.
- Analysis of the physiological impact of fasting and the introduction of enteral feedings.
Main Results:
- Early initiation of enteral feedings, within two weeks of starting TPN, appears beneficial in preventing or reducing cholestasis.
- The nutritional content of early enteral feedings may be less critical than the act of feeding itself to interrupt fasting physiology.
Conclusions:
- Enteral feeding should be introduced early in neonates receiving TPN to prevent cholestasis.
- Further research is needed to understand TPN-associated cholestasis pathogenesis and to establish safe and effective prophylactic and therapeutic strategies.
Abstract:
It appears that neonates, especially those with very low birthweights, may be at especially high risk of developing cholestasis associated with total parenteral nutrition (TPN). Within 2 weeks of starting intravenous alimentation, it would appear highly desirable to be able to start at least small enteral feedings to interrupt the physiology of fasting. Such feedings may not have to be of much nutritional benefit to improve cholestasis. Calorie and amino acid intake should be limited to the requirements of the infant being treated. Whether protection of the TPN infusate from light is of benefit remains to be determined. Drug therapies for TPN-associated cholestasis of infancy have not been proven safe or effective. Additional investigations to further clarify the pathogenesis of this syndrome, and clinical studies of prophylaxis and therapy, are needed to enhance our ability to provide nutritionally effective and metabolically safe parenteral nutrition.